MEDICATION-ASSISTED TREATMENT CENTERS OF EXCELLENCE

June 13th, 2023 **BIWEEKLY NEWSLETTER** Vol. 76



FDA APPROVES NEW BUPRENORPHINE TREATMENT OPTION FOR OPIOID USE DISORDER

The FDA has approved Brixadi (buprenorphine) extended-release injection for subcutaneous use to treat severe OUD. Brixadi will be available through a Risk Evaluation and Mitigation Strategy program and can only be administered by health care providers in health care settings. It is available as a weekly injection for patients starting treatment, and monthly injection for patients already on treatment. Weekly doses are 8 mg, 16 mg, 24 mg, and 32 mg. Monthly doses are 64 mg, 96 mg, and 128 mg.

WHAT'S INSIDE

UPCOMING EVENTS

6/15: Best Practices in Trauma Informed OD Prevention Conference

6/15: OBAT Monthly SUD Navigation Support Calls

6/22: NJ Opioid Recovery & Remediation Fund Advisory Council

7/6: ECHO: Naloxone Administration in the Age of Fentanyl

HEADLINES

Public Health & Medical Preparedness for Mass Casualties from Deliberate Release of Synthetic Opioids

Safety & Preliminary Outcomes of SOAT for Hospitalized Patients with OUD

Determinants of Health-Related Quality of Life Among Individuals with OUD Recently Released from Incarceration

RESOURCES

Pharmacist's Role in NJ Naloxone 365 Program

UPCOMING EVENTS



BEST PRACTICES IN TRAUMA INFORMED OVERDOSE PREVENTION CONFERENCE

THURSDAY, JUNE 15TH, 2023 (9AM-3:30PM)

As NJ looks to strengthen and expand the overdose prevention and recovery ecosystem, it's critical to reflect on past successes and challenges and dive deeper into the data to ensure forward progress. Join to understand better which communities are being disproportionately impacted and hear from leaders and changemakers across the country that are innovating care and saving lives.

NJ OPIOID RECOVERY & REMEDIATION FUND ADVISORY COUNCIL

THURSDAY, JUNE 22ND, 2023 (11AM-1PM)

ESSEX COUNTY COLLEGE
CLARA E. DASHER STUDENT CENTER
303 UNIVERSITY AVENUE, NEWARK, NJ

In addition to the input already received through the online portal, the NJ Opioid Recovery and Remediation Fund Advisory Council is holding listening sessions to gather public input on distributing opioid settlement funds. NJ will receive at least $641 million over 18 years as part of a federal opioid settlement.

OBAT MONTHLY SUD NAVIGATION SUPPORT CALLS

THURSDAY, JUNE 15TH, 2023 (12-1 PM)

In addition to Camden Coalition's main SUD Navigator Training, they are offering monthly resource calls and skills labs to provide ongoing opportunity for OBAT navigators and other SUD navigators / case managers to continue learning through:

- Hour long deep dive of particular content areas;
- Discussion of (de-identified) patient cases and support thinking through patient engagement strategies, potential resources, and how to practice self-care while doing this work;
- Presentations and sharing updated resources about relevant topics such as harm reduction, strategies for identifying new community resources, telemedicine during the COVID-19 pandemic, and more.

SUD PROJECT ECHO: NALOXONE ADMINISTRATION IN THE AGE OF FENTANYL

THURSDAY, JULY 6TH, 2023 (12 PM-1 PM)

At every live ECHO session we explore active patient challenges from multiple perspectives. We each hold a piece of the puzzle and everyone is welcome to share experiences. You'll meet practitioners from across the state through a simple video interface and become part of a collegial community. You'll have a comfortable place to return and build on what you're learning, month to month.

RECENT NEWS

PUBLIC HEALTH AND MEDICAL PREPAREDNESS FOR MASS CASUALTIES FROM THE DELIBERATE RELEASE OF SYNTHETIC OPIOIDS

Since 2013, the world has witnessed the growth of opioid overdose deaths with a large proportion of those deaths due to synthetic opioids. In 2021, 88% of opioid overdose deaths were allotted to synthetic opioids, increasing by 22% from 2020.


Synthetic opioids are:

- highly potent,
- fast acting,
- can cause respiratory depression,
- are widely accessible,
- and have **potential to be distributed for mass exposure** through inhalation or ingestion.

The objective of this paper is to **raise awareness of the health consequences and risks of a deliberate release of synthetic opioids and educate on concepts to enhance preparedness for such an incident.**

·SAFETY AND PRELIMINARY OUTCOMES OF SHORT-ACTING OPIOID AGONIST TREATMENT (SOAT) FOR HOSPITALIZED PATIENTS WITH OPIOID USE DISORDER

Twenty-five to thirty percent of patients who inject drugs leave the hospital prematurely often due to untreated withdrawal and pain. This is considered a patient-directed discharge. This study was a pharmacist-guided pilot, implementing short-acting opioid agonist treatment (sOAT) for hospitalized patients with OUD at an academic hospital in Philadelphia, PA. sOAT is an alternative approach that uses short-acting opioids for treatment of pain and withdrawal while offering traditional OUD treatment. The goal was to prove that sOAT was safe and effective. They found that **pain and withdrawal symptoms were lower on the third day of sOAT** and **overall lower rate of patient directed discharges**. sOAT was **found to be safe**. It is important to note that patient directed discharges are not limited to pain and withdrawal.



RECENT NEWS


DETERMINANTS OF HEALTH-RELATED QUALITY OF LIFE AMONG INDIVIDUALS WITH OPIOID USE DISORDER, RECENTLY RELEASED FROM INCARCERATION

This secondary longitudinal analysis aimed to understand the factors that influence health-related quality of life among individuals with OUD during the transition period from incarceration to community. Findings showed that increased mental health complications were strongly associated with reduced health-related quality of life following release. **These findings highlight the importance of ensuring individuals with OUD are linked with both MOUD and treatment for comorbid conditions upon release from prison.**

RESOURCES

THE COMMUNITY PHARMACIST'S ROLE IN NJ'S NALOXONE 365 PROGRAM

Naloxone, an opioid antidote, is a vital harm reduction tool that has significant barriers to access due to cost and stigma. DMHAS has implemented the NJ "Naloxone 365" program to remove barriers to this lifesaving medication by making it more accessible to individuals requesting naloxone in community pharmacies. The main objective of this program is to explain the importance of "Naloxone 365," so that community pharmacies are provided with the tools and information to effectively execute this program. *This free course is presented by our Clinical Pharmacist/Academic Detailer, Dr. Clement Chen, and provided by the NJ Pharmacists Association, and the NJ DHS. Credit will be awarded only after successful completion of the timed webinar, quizzes and an evaluation.*



MEDICATION-ASSISTED TREATMENT
CENTERS OF EXCELLENCE

24/7 MAT Provider Hotline: 844-HELP OUD (844-435-7683)

Northern NJ MAT COE Website & Email
Southern NJ MAT COE Website & Email